chemotherapy - Physician's Weekly



New Guidelines for Head & Neck Cancer Reirradiation

Recurrent and second primary head-and-neck squamous cell carcinomas (HNSCC) arising within or close to previously irradiated areas are a significant clinical challenge. Salvage surgical resection is the standard of care, but...

Agent Approved for Highly Toxic Chemotherapy Levels

The FDA has approved glucarpidase (Voraxaze, BTG International) for treating patients with toxic levels of methotrexate—a type of chemotherapy—in the blood due to kidney failure. The drug breaks down methotrexate to a form that...

The Impact of Complications on Colorectal Cancer Care

Colorectal cancer (CRC) is diagnosed in almost 150,000 patients in the United States each year and is the second leading cause of cancer-related death, accounting for more than 50,000 mortalities annually. The use of adjuvant...

Updated Practice Guidelines for Ovarian Cancer

A major challenge in treating ovarian cancer is that by the time most patients are diagnosed with the disease, it has already progressed to stage III or IV. The difficult-to-examine location of the ovaries deep in the pelvis...

Preventing Delayed CINV to Improve Patient Outcomes

Chemotherapy-induced nausea and vomiting (CINV) remains a major adverse effect of cancer chemotherapy, despite the availability of several antiemetic drug classes. Although not life-threatening, CINV has a major impact on a...

American Society of Clinical Oncology 2010

The American Society of Clinical Oncology, or ASCO, held its 2010 annual meeting from June 4 to 8 in Chicago. The features below highlight some of the news emerging from the meeting. » A New Screening Strategy for Ovarian Cancer...




For latest news and updates
Email-id is invalid